Related Experiment Video
Updated: Jan 29, 2026

Establishment of a High-throughput Setup for Screening Small Molecules That Modulate c-di-GMP Signaling in Pseudomonas aeruginosa
Published on: June 30, 2016
Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses
Denis T Akan1, Jennifer E Howes1, Jiqing Sai1
1Department of Biochemistry , Vanderbilt University School of Medicine , 2215 Garland Avenue, 607 Light Hall , Nashville , Tennessee 37232-0146 , United States.
Abstract:
Activating mutations in RAS can lead to oncogenesis by enhancing downstream signaling, such as through the MAPK and PI3K pathways. Therefore, therapeutically targeting RAS may perturb multiple signaling pathways simultaneously. One method for modulating RAS signaling is to target the activity of the guanine nucleotide exchange factor SOS1. Our laboratory has discovered compounds that bind to SOS1 and activate RAS. Interestingly, these SOS1 agonist compounds elicit biphasic modulation of ERK phosphorylation and simultaneous inhibition of AKT phosphorylation levels. Here, we utilized multiple chemically distinct compounds to elucidate whether these effects on MAPK and PI3K signaling by SOS1 agonists were mechanistically linked. In addition, we used CRISPR/Cas9 gene-editing to generate clonally derived SOS1 knockout cells and identified a potent SOS1 agonist that rapidly elicited on-target molecular effects at substantially lower concentrations than those causing off-target effects. Our findings will allow us to further define the on-target utility of SOS1 agonists.
Insights
Targeting SOS1 with novel agonists modulates RAS signaling, impacting both MAPK and PI3K pathways. Researchers identified a potent SOS1 agonist with rapid, on-target effects, advancing therapeutic strategies for RAS-driven cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Activating RAS mutations drive oncogenesis via MAPK and PI3K pathways.
- Targeting RAS signaling pathways is a key therapeutic strategy.
- SOS1 (Son of Sevenless homolog 1) is a guanine nucleotide exchange factor that modulates RAS activity.
Purpose of the Study:
- To investigate the mechanistic link between SOS1 agonist activity and downstream signaling modulation.
- To explore the therapeutic potential of SOS1 agonists in RAS-driven oncogenesis.
- To identify potent SOS1 agonists with specific on-target effects.
Main Methods:
- Utilized chemically distinct SOS1 agonist compounds.
- Employed CRISPR/Cas9 gene-editing to generate SOS1 knockout cells.
- Analyzed ERK and AKT phosphorylation levels to assess pathway modulation.
Main Results:
- SOS1 agonists demonstrated biphasic modulation of ERK phosphorylation and simultaneous inhibition of AKT phosphorylation.
- Distinct SOS1 agonists were used to confirm mechanistic links in signaling effects.
- A potent SOS1 agonist was identified, eliciting rapid on-target effects at low concentrations.
Conclusions:
- SOS1 agonists can simultaneously modulate MAPK and PI3K signaling pathways.
- CRISPR/Cas9-generated SOS1 knockout cells aided in elucidating on-target effects.
- Findings support the further definition of SOS1 agonists for therapeutic utility in RAS-driven cancers.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Types of Signaling Molecules
Inflammatory Response I: Vascular and Cellular
Diversity in Cell Signaling Responses
Graded and Abrupt Responses
Some signaling systems generate...
Introduction to Test of Independence
The test statistic for a test of independence is similar to that of a goodness-of-fit test: